Pediatrics & Therapeutics
Open Access

Cardiovascular and Off-label Drugs Therapy in Pediatrics

Ezequiel Johnels^{* *}Correspondence: Ezequiel Johnels, Department of Paediatrics, University of Gothenburg, Gothenburg, Sweden, Email:

Author info »

Description

Children have a similar right to accredited and safe medicines as adults. The Pediatric specialty Regulation enacted in 2007 within the EU aimed to increase the amount of safe medicines for children. The 10-year report showed that pediatric desires were still being neglected and drug development was driven rather by adult needs. Medication used in paediatrics are usually prescribed outside what's urged within the product information, “off-label”. The prevalence of off-label prescription ranges from 15% to 70% in paediatrics and from 32% to 78% in pediatric cardiology. At one pediatric intensive care unit, over 90% of patients used a minimum of one drug off-label.

Off-label drug usage deviates from the accredited product info as regards either indication, age of patient, dosage, formulation, or route of administration [1]. Off-label drug usage has been related to a hyperbolic risk of adverse drug reaction, twofold to threefold that of on-label usage. It may also cause ineffective therapy due to under dosing, and is related to a longer stay at a Pediatric Cardiac Intensive Care Unit (pCICU), longer hospital stay, and higher mortality.

Children differ from adults in body size and composition as well as within the maturation of organs and pharmacodynamics responses to a drug in terms of pharmacology, that is, absorption, distribution, metabolism, and elimination of the substance. All of these factors create pediatric pharmacotherapy challenging. Lack of clinical trials within the Summary of Product Characteristics (SmPC) is the most frequent cause for prescription in children being classified as off-label.

Due to the shortage of licensed medicines, drug prescriptions in pediatrics usually depend on experience-based data and high quality academic trials and research [2]. Such prescriptions are stated as “on-evidence”. We tend to hypothesized that off-label use of medicine in pediatric cardiology would still be common, however that evidence shared and clinical support systems would possibly support the off-label use of specific drugs. The aim of this study was to spot support used for drug treatments at cardiac wards and pCICUs.

The use of off-label treatment in pediatric cardiac care is common in Sweden and each patient during this study was on a minimum of one off-label drug treatment. In total, 170 (70%) drug treatments were off-label, but most of the prescriptions were relating to the chosen drug from other clinical decision support sources. The common use of off-label drug treatments in our study is in line with results from other studies on drugs used in cardiac pediatric patients (33%-80%). Use of off-label medication at the pCICUs in our study was hyperbolic or almost like that seen in other studies from pCICUs or general pediatric intensive care units. Analgesics and cardiovascular drugs were the foremost unremarkably used medication.

Lack of pediatric indication within the product info was the fourth commonest reason for the drug to be classified to be used off-label use, whereas this has usually been found to be the main cause behind off-label drug use. However, the utilization of unlicenced and insufficiently studied medicines, even with a basis in shared expertise, will increase the risks of sudden adverse drug reactions and under dosing causing ineffective drug therapy [3]. Extrapolation of drug efficacy from clinical trials in adults to the pediatric population could minimize the exposure of children to clinical trials, however medical product safety in children should be increased through pediatric clinical trials in children of various ages, since neonates, children, and adolescents differ in many aspects.

Children of all ages are liable to drug-induced growth and development disorders as well as delayed adverse drug reactions that aren't found in adults. Further, adverse drug reactions are also troubles interpret among children at young ages. Safe and effective pharmacotherapy is based on 3 pillars-the right indefinite quantity, efficacy, and safety-in accordance with the principles of evidence-based drugs. Further, sharing of medical experience cannot meet this need; the long follow-up needed on adverse drug reactions isn't self-addressed and studies on this are necessary.

The national approach of this study, together with Sweden’s entire operative and tubing intervention centers for pediatric cardiology could be strength. Thus, it's likely that medication used in this study are associated with the care of severely ill patients, with other medical desires, as an example, relating to pain relief and sedation, than the common cardiac patient [4,5]. This can, in turn, introduce choice bias and limit comparisons to other studies together with cardiac outpatients. As this was a cross-sectional study performed throughout one single day at every center, there was a spread in time to and after surgery among the patients, and therefore selection bias due to patient selection was small.

Information on drug treatment was retrieved alone from medical records. For a few medications, there was no information on medical indications for a selected drug. If no indication may be known, the treatment was labeled “unknown,” instead of off-label. This limits the study, because the variety of enclosed medication and treatments decreased, however increased validity as only drugs with clear indications were enclosed.

References

1. Kimland E, Odlind V, Bottiger Y, Lindemalm S. Paediatric drug use with focus on off‐label prescriptions at Swedish hospitals—a nationwide study. Acta Paediatrica. 2012;101:772‐778.

   [CrossRef] [Google Scholar] [PubMed]

2. Conroy S, Choonara I, Impicciatore P. Survey of unlicensed and off label drug use in paediatric wards in European countries. European network for drug investigation in children. BMJ. 2000;320(7227):79‐82.

   [CrossRef] [Google Scholar] [PubMed]

3. Palmaro A, Bissuel R, Renaud N. Off‐label prescribing in pediatric outpatients. Pediatrics. 2015;135(1):49‐58.

   [CrossRef] [Google Scholar] [PubMed]

4. Pasquali SK, Hall M, Slonim AD, Jenkins KJ, Marino BS, Cohen MS, et al. Off‐label use of cardiovascular medications in children hospitalized with congenital and acquired heart disease. Circ Cardiovasc Qual Outcomes. 2008;1(2):74‐83.

   [CrossRef] [Google Scholar] [PubMed]

5. Maltz LAK, Spaeder D, Wessel MC. Off‐label drug use in a single‐center pediatric cardiac intensive care unit. World J Pediatr Congen Heart Surg. 2013;4(3):262‐266.

   [CrossRef] [Google Scholar] [PubMed]